Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study

J Clin Endocrinol Metab. 2021 Mar 8;106(3):774-788. doi: 10.1210/clinem/dgaa849.

Abstract

Context: Few studies have examined the clinical characteristics that predict durable, long-term diabetes remission after bariatric surgery.

Objective: To compare diabetes prevalence and remission rates during 7-year follow-up after Roux-en-Y gastric bypass (RYGB) and laparoscopic gastric banding (LAGB).

Design: An observational cohort of adults with severe obesity recruited between 2006 and 2009 who completed annual research assessments for up to 7 years after RYGB or LAGB.

Setting: Ten US hospitals.

Participants: A total sample of 2256 participants, 827 with known diabetes status at both baseline and at least 1 follow-up visit.

Interventions: Roux-en-Y gastric bypass or LAGB.

Main outcome measures: Diabetes rates and associations of patient characteristics with remission status.

Results: Diabetes remission occurred in 57% (46% complete, 11% partial) after RYGB and 22.5% (16.9% complete, 5.6% partial) after LAGB. Following both procedures, remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher homeostatic model assessment of β-cell function (HOMA %B), and lower insulin usage at baseline, and with greater postsurgical weight loss. After LAGB, reduced HOMA insulin resistance (IR) was associated with a greater likelihood of diabetes remission, whereas increased HOMA-%B predicted remission after RYGB. Controlling for weight lost, diabetes remission remained nearly 4-fold higher compared with LAGB.

Conclusions: Durable, long-term diabetes remission following bariatric surgery is more likely when performed soon after diagnosis when diabetes medication burden is low and beta-cell function is preserved. A greater weight-independent likelihood of diabetes remission after RYGB than LAGB suggests mechanisms beyond weight loss contribute to improved beta-cell function after RYGB.Trial Registration clinicaltrials.gov Identifier: NCT00465829.

Keywords: beta-cell function; diabetes; gastric bypass; laparoscopic gastric band; remission.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Bariatric Surgery* / statistics & numerical data
  • Diabetes Complications / epidemiology
  • Diabetes Complications / surgery
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Obesity, Morbid / complications
  • Obesity, Morbid / epidemiology
  • Obesity, Morbid / surgery*
  • Outcome Assessment, Health Care
  • Remission Induction
  • Treatment Outcome
  • United States / epidemiology

Associated data

  • ClinicalTrials.gov/NCT00465829